Patent · US Active

Pharmaceutical composition containing a stabilised mRNA optimised for translation in its coding regions

US11135312B2 · kind B2 · utility

28Cited by

45References

16Claims

0Family size

Assignee

CureVac AG · DE

Inventors

Florian Von Der Mülbe · Stuttgart, DE
Ingmar Hoerr · Tübingen, DE
Steve Pascolo · Tübingen, DE

Key dates

Filing date	Sep 16, 2014
Grant date	Oct 5, 2021
Priority date	—
Expiry date	Feb 22, 2038

Classification

Technology area (CPC G)Physics
CPC primaryG16B30/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to a pharmaceutical composition comprising a modified mRNA that is stabilised by sequence modifications and optimised for translation. The pharmaceutical composition according to the invention is particularly well suited for use as an inoculating agent, as well as a therapeutic agent for tissue regeneration. In addition, a process is described for determining sequence modifications that promote stabilisation and translational efficiency of modified mRNA of the invention.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.